Literature DB >> 26687059

Apocynin ameliorates endotoxin-induced acute lung injury in rats.

Marwa E Abdelmageed1, Mohammed S El-Awady1, Ghada M Suddek2.   

Abstract

Acute lung injury (ALI) is a serious clinical syndrome with a high rate of mortality. In this study, the effects of apocynin, a NADPH-oxidase (NOX) inhibitor on lipopolysaccharide (LPS)-induced ALI in rats were investigated. Male Sprague-Dawley rats were treated with apocynin (10mg/kg) intraperitoneally (i.p.) 1h before LPS injection (10mg/kg, i.p.). The results revealed that apocynin attenuated LPS-induced ALI as it decreased total protein content, lactate dehydrogenase (LDH) activity and the accumulation of the inflammatory cells in the bronchoalveolar lavage fluid (BALF), In addition, apocynin significantly increased superoxide dismutase (SOD) and reduced glutathione (GSH) activities with significant decrease in the lung malondialdehyde (MDA) content as compared to LPS group in lung tissue and decreased pulmonary artery contraction induced by LPS. It also upregulated mRNA expression of inhibitory protein kappaB-alpha (NFκBia) and downregulated mRNA expression of Toll-Like receptor 4 (TLR4) and decreased inflammation observed in lung tissues. Collectively, these results demonstrate the protective effects of apocynin against the LPS-induced ALI in rats through its antioxidant and antiinflammatory effect that may be attributed to the decrease in mRNA expression of TLR4 and increasing that of NFκBia.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute lung injury; Apocynin; Lipopolysaccharide; NFκBia; Rats

Mesh:

Substances:

Year:  2015        PMID: 26687059     DOI: 10.1016/j.intimp.2015.12.006

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  8 in total

1.  Effects of glycyrrhizin on lipopolysaccharide-induced acute lung injury in a mouse model.

Authors:  Song Am Lee; Seung Hyun Lee; Jin Yong Kim; Woo Surng Lee
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

2.  Changes of Lipopolysaccharide-Induced Acute Kidney and Liver Injuries in Rats Based on Metabolomics Analysis.

Authors:  Huan Gao; Tao Yang; Xuan Chen; Yanqing Song
Journal:  J Inflamm Res       Date:  2021-05-06

3.  Anti-inflammatory Effects of Pelargonium endlicherianum Fenzl. Extracts in Lipopolysaccharide-stimulated Macrophages.

Authors:  Ahmet Cumaoğlu; Gökçe Şeker Karatoprak; Mükerrem Betül Yerer; Müberra Koşar
Journal:  Turk J Pharm Sci       Date:  2018-04-02

4.  Myricitrin Modulates NADPH Oxidase-Dependent ROS Production to Inhibit Endotoxin-Mediated Inflammation by Blocking the JAK/STAT1 and NOX2/p47phox Pathways.

Authors:  Shimei Qi; Zunyong Feng; Qiang Li; Zhilin Qi; Yao Zhang
Journal:  Oxid Med Cell Longev       Date:  2017-06-20       Impact factor: 6.543

5.  Unfractionated heparin ameliorates pulmonary microvascular endothelial barrier dysfunction via microtubule stabilization in acute lung injury.

Authors:  Shengtian Mu; Yina Liu; Jing Jiang; Renyu Ding; Xu Li; Xin Li; Xiaochun Ma
Journal:  Respir Res       Date:  2018-11-15

6.  ROS Signaling in the Pathogenesis of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).

Authors:  Manuela Kellner; Satish Noonepalle; Qing Lu; Anup Srivastava; Evgeny Zemskov; Stephen M Black
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

7.  Inhibition of Peroxiredoxin 6 PLA2 Activity Decreases Oxidative Stress and the Severity of Acute Lung Injury in the Mouse Cecal Ligation and Puncture Model.

Authors:  Aron B Fisher; Chandra Dodia; Jian-Qin Tao; Sheldon I Feinstein; Shampa Chatterjee
Journal:  Antioxidants (Basel)       Date:  2021-10-24

8.  C16, a novel sinomenine derivatives, promoted macrophage reprogramming toward M2-like phenotype and protected mice from endotoxemia.

Authors:  Ping Ni; Yue-Qin Liu; Jin-Yu Man; Wang Li; Shan-Shan Xue; Tao-Hong Lu; Zhao-Liang Su; Cheng-Lin Zhou
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.